Skip to content

The HIV PrEP and Microbicides Pipeline

July 2018 by Jeremiah Johnson Since 2011, HIV prevention has undergone a true revolution. With three major studies (HPTN 052, PARTNER, and Opposites Attract) now showing zero new infections linked to an HIV positive person who has successfully suppressed their…

Read more

The Antiretroviral Pipeline

July 2018 by Tim Horn The past 12 months has been historic in terms of the number of new HIV treatment modalities reaching pharmacy shelves, at least in the United States. Four originator products – the first dual-drug regimen for…

Read more

The HCV Treatment Pipeline

July 2018 Annette Gaudino HCV TREATMENT PIPELINE: THE DEFERRED DREAM OF TREATMENT FOR ALL Generic combinations of direct-acting antivirals (DAAs), including sofosbuvir/daclatasvir show bioequivalence compared to originators with equivalent sustained virological responses (SVR). Both sofosbuvir/daclatasvir and sofosbuvir/ravidasvir demonstrate SVR rates…

Read more

The HCV Diagnostics Pipeline

July 2018 by Bryn Gay Simpler Rapid, Point-of-Care Hepatitis C Diagnostics: Are We There Yet?1 To increase treatment rates and make a dent in the epidemic by 2030, countries need to scale up access to affordable, simple, rapid diagnostics, ensuring…

Read more

Preventive Technologies: Antiretroviral and Vaccine Development

July 2017 By Jeremiah Johnson and Richard Jefferys INTRODUCTION Recent advances in the research, development, and implementation of biomedical HIV prevention—primarily in the form of treatment as prevention (TasP) and tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC) as pre-exposure prophylaxis (PrEP)—already…

Read more

The TB Prevention Pipeline

July 2017 By Mike Frick INTRODUCTION One of the tuberculosis (TB) field’s most often voiced truisms has been that one-third of humanity is infected with Mycobacterium tuberculosis (MTB), the causative agent of TB disease. This estimate is invoked so frequently…

Read more
Back To Top